Characteristics and effects of female hormones used by male transsexuals in Lima, Peru
Descripción del Articulo
Introduction: In the feminization process, some male transsexuals use synthetic female hormones whose safety has not been defined in genetically male persons. Objectives: To evaluate the degree of knowledge, frequency of use, type of administration, adverse effects and source of information on femal...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2014 |
| Institución: | Universidad Nacional Mayor de San Marcos |
| Repositorio: | Revistas - Universidad Nacional Mayor de San Marcos |
| Lenguaje: | español |
| OAI Identifier: | oai:ojs.csi.unmsm:article/10844 |
| Enlace del recurso: | https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/10844 |
| Nivel de acceso: | acceso abierto |
| Materia: | Transexualismo feminización hormonas femeninas gonadales |
| Sumario: | Introduction: In the feminization process, some male transsexuals use synthetic female hormones whose safety has not been defined in genetically male persons. Objectives: To evaluate the degree of knowledge, frequency of use, type of administration, adverse effects and source of information on female hormones in male transsexual persons. Design: Qualitative and quantitative community prospective study. Place: Lima. Participants: Male transsexuals 18 years old or older who had been using female hormones for 6 months or more. Interventions: Four trained male transsexuals identified new male transsexual by the ‘snow ball’ method. Then, subjects were interviewed, underwent physical examination, and a 10 mL blood sample was obtained. Main outcome measures: Level of knowledge, quality of information received, acquisition source, and side effects of female hormones. Results: Only 11.8% of the participants obtained the hormones by medical prescription and had some knowledge about its effects. Most common side effects were breast tenderness and weight gain (88.2%), and decline of libido and erection (58.8%). A combination of dihydroxyprogesterone plus estriol IM was the most common female hormone used (47.1%). Conclusions: Implementation of multidisciplinary services that meet the health needs of this population is necessary to decrease the risks. |
|---|
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).